Press Releases

Date Title and Summary Additional Formats
Toggle Summary Retrophin Proposes Acquisition of Transcept for $4.00 Per Share
NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB:RTRX) today announced that it has made a proposal to the Board of Directors of Transcept Pharmaceuticals, Inc. (Nasdaq:TSPT) to acquire all of the shares of Transcept common stock that Retrophin does not own for $4.00 per share in cash.
View HTML
Toggle Summary Retrophin to Present at the Stifel Healthcare Conference 2013
Corporate Overview Presentation Wednesday, September 11, 2013 at 4:25pm ET NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB: RTRX) today announced that Martin Shkreli , Founder, President and Chief Executive Officer, will present an overview of the Company at the Stifel Healthcare Conference
View HTML
Toggle Summary Retrophin, Inc. Raises $25 Million in Private Placement Financing
Retrophin, Inc. Raises $25 Million in Private Placement Financing New York, NY (August 16, 2013) , Retrophin, Inc. (OTCQB: RTRX), today announced that it has entered into definitive agreements with a number of new and existing institutional investors in connection with a private placement, or PIPE,
View HTML
Toggle Summary Retrophin Signs Exclusivity Agreement with a Major Pharmaceutical Company to Negotiate a License to a Product to be Developed for Autism and Schizophrenia
NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB: RTRX) today announced that it has signed an agreement with a major pharmaceutical company for the exclusive right to negotiate a royalty-bearing U.S. license for a product to be developed for the treatment of Autism and Schizophrenia.
View HTML
Toggle Summary Retrophin Reports Positive Survival Data from Preclinical Trial of RE-024 for the Treatment of the Ultra-Orphan Disease Pantothenate Kinase-Associated Neurodegeneration (PKAN)
Company to Hold Update Conference Call Today, August 16, 2013 at 10:00 a.m. ET NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB: RTRX) today announced that it has received positive survival results from interim preclinical tests for the Company's compound, RE-024, for the treatment of the
View HTML
Toggle Summary Retrophin Expands Management Team with Appointment of Steven R. Eby, R.Ph as Vice President, Global Strategy and Program Management
Retrophin Expands Management Team with Appointment of Steven R. Eby, R.Ph as Vice President, Global Strategy and Program Management NEW YORK--(BUSINESS WIRE)-- Retrophin, Inc. ( RTRX ), a pharmaceutical company focused on the discovery and development of drugs for the treatment of catastrophic
View HTML
Toggle Summary Retrophin Names Marc L. Panoff as Chief Financial Officer
Retrophin Names Marc L. Panoff as Chief Financial Officer New York, NY (May 8, 2013) – Retrophin, Inc. (OTCQB: RTRX) today announced that it has named Marc L. Panoff, CPA, MBA as Chief Financial Officer and Chief Accounting Officer, effective May 20.
View HTML
Toggle Summary Retrophin Names Horacio Plotkin, M.D. as Chief Medical Officer
Brings wealth of clinical research and regulatory submission expertise to help advance pipeline
View HTML
Toggle Summary Retrophin Sponsors Seventh International NBIA Disorders Association Family Conference
Overview of RE-024 for PKAN presented
View HTML
Toggle Summary Retrophin Announces Positive Results from Preclinical Studies of RE-024 for PKAN
New York, NY (March 11, 2013) – Retrophin, Inc. (OTCQB: RTRX), a biotechnology company focused on the discovery and development of orphan drugs for the treatment of rare and life-threatening diseases for which there are currently no viable patient options, today announced positive results
View HTML